Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy
NCT01068470
·
clinicaltrials.gov ↗
TERMINATED
Status
11
Enrollment
OTHER
Sponsor class
Stopped
PI left the institution
Conditions
Melanoma
Kidney Cancer
Sponsor
Loma Linda University